Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: VITRIVAX, INC.
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2023-01-12 to 2025-02-11
Current total value of award: $9100796.39
Description: OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS